Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics of Julphar Insulin R and Huminsulin® Normal
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
This study in healthy volunteers aimed to demonstrate similar PK and PD properties of the new
short-acting human soluble insulin, Julphar Insulin R, and the already approved reference
insulin, Huminsulin® Normal. The trial participants received both study treatments on two
separate dosing days.
Phase:
Phase 1
Details
Lead Sponsor:
Julphar Gulf Pharmaceutical Industries
Collaborators:
Parexel Profil Institut für Stoffwechselforschung GmbH